Medical device companies Abbott, Boston Scientific, Johnson & Johnson, and Medtronic are trying to come to grips with Indian regulators’ decision to set a price cap on cardiac stents by refiling applications to withdraw certain products, as well as lobbying against such regulation, which they contend increases the risk of introducing new products into the country and places such products out of patients’ reach.
Boston Scientific's chief executive says the company intends to continue its momentum achieving top-line growth across all business segments, and is preparing to re-introduce its Lotus device into the burgeoning transcatheter aortic valve replacement (TAVR) market in 2017’s fourth quarter.
Zimmer Biomet CEO David Dvorak told investors that the company will build on gains achieved during the first quarter as the company ramps up production in its Warsaw facility, which is subject to ongoing remediation activities.
Edwards Lifesciences reported better-than-expected first quarter numbers behind surging sales of its transcatheter aortic valve replacement (TAVR) devices.
Philips' HealthTech portfolio powered the company's first quarter performance, and growth is expected to accelerate through 2017, despite weakness in the United States market related to potential healthcare policy changes.
Becton Dickinson (BD) is paying $24 billion in cash and stock to acquire C. R. Bard to move beyond diabetes care and into peripheral vascular disease, urology, hernia, and cancer treatments, as well as to round out its market-leading medication management portfolio.
Danaher Corporation's recent acquisitions, reinvestments, and the Chinese market will continue to help drive long-term growth, according to the company's CEO, Thomas P. Joyce, Jr.
Abbott CEO Miles White is optimistic that the company will overcome remaining hurdles to complete the purchase of Alere by the end of the third quarter, and that it will clear up manufacturing quality issues involving a plant acquired from St. Jude Medical.
Johnson & Johnson (J&J) says it is making good progress with ongoing restructuring of its medical device business, but the company still is considering various options for its diabetes unit, including potential partnerships or divestitures.
Abbott Laboratories has agreed to proceed with its purchase of diagnostics firm Alere — for $500 million less than its original price offer.